TAA T-Cell Therapy Keeps 3 Children Cancer-Free for 2.5 Years in Phase 1 Trial
Updated
Updated · Scientific American · Jul 14
TAA T-Cell Therapy Keeps 3 Children Cancer-Free for 2.5 Years in Phase 1 Trial
3 articles · Updated · Scientific American · Jul 14
Summary
Three children with recurrent aggressive brain tumors were alive without further treatment more than 2.5 years after receiving experimental TAA T-cell therapy, and one child's cancer disappeared completely.
The phase 1 study tested a treatment that expands each patient's own T cells that naturally recognize three proteins commonly expressed by pediatric brain tumors, then infuses them back to attack the cancer.
The therapy was generally well tolerated, but two patients developed serious tumor swelling and one child with an aggressive brain stem tumor died from treatment-related complications at the highest dose tested.
Researchers and outside specialists called the results encouraging rather than definitive, saying larger trials are still needed to show whether the therapy can reliably improve survival in deadly childhood brain cancers.
As T-cell therapy shows promise, is the ultimate cure a treatment genetically matched to each child's individual tumor?
A new therapy saved four children from brain cancer. Can ultrasound now break the final barrier to a universal cure?
An experimental therapy worked for some children but not others. What is the hidden biological key to its success?
TAA-T Cell Therapy Achieves Long-Term Survival in Pediatric Brain Tumors: Breakthrough Results and Future Directions
Overview
TAA T-cell therapy is a new, personalized treatment for pediatric brain tumors that uses a patient’s own immune system to fight cancer. The process starts by collecting T-cells from the patient’s blood, then training these cells in the lab to recognize three specific protein markers found on tumor cells. The trained T-cells are multiplied and returned to the patient through an IV. Once inside the body, these specialized T-cells help the immune system target and destroy cancer cells more effectively, offering hope for children who have run out of standard treatment options.